Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.108562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Chen Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., Ltd., Jinan,250100, PR China. Hauptthemen laut MEDLINE: Histone Deacetylase 6, Histone Deacetylase Inhibitors, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Scientific Research Foundation of Hunan Provincial Education Department, Natural Science Foundation of Shandong Province, Taishan Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
In stark contrast to other HDAC isoforms, deletion or inhibition of HDAC6 suppresses cell proliferation without lethality or defective phenotypes, thereby establishing HDAC6 as a compelling anti-cancer target. In pursuit of safe and effective anti-cancer chemotherapy, we preformed three-round structural optimization and developed several potent HDAC6-selective inhibitors. Among these, HDSI-18 exhibited remarkable inhibitory activity (IC50 = 1.6 nM) and exceptional isoform selectivity (over 975-fold) against HDAC6. Further biological evaluations highlighted the promising properties of HDSI-18 in terms of anti-proliferative activity, mitochondrial depolarization, caspase-3 activation, apoptosis induction and druggability (both in vivo and in vitro). This study demonstrated a paradigm for the rational structural optimization of HDAC6 selective inhibitors, which may serve as a beacon for the development of more promiscuous compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., Ltd., Jinan,250100, PR China.
- Department of Stomatology, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia.
- Key Laboratory of Theoretical Organic Chemistry and Functional Molecule, Ministry of Education, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, Hunan 411201, PR China.
- Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, PR China.
- Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China.
- Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China. Electronic a…
Förderung
- Scientific Research Foundation of Hunan Provincial Education Department
- Natural Science Foundation of Shandong Province
- Taishan Scholar Foundation of Shandong Province
- Taishan Scholar Project of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, C., Ma, X., Wan, Y., Zhong, Y., Hou, X., Fang, H., & Liang, T. (2025). Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108562
Vancouver
Chen C, Ma X, Wan Y, Zhong Y, Hou X, Fang H, et al. Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108562
BibTeX
@article{Chen2025,
author = {Chen, Chen and Ma, Xiaochun and Wan, Yichao and Zhong, Yidong and Hou, Xuben and Fang, Hao and Liang, Tao},
title = {Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.108562}
}
EUVIMED